Meningococcal Disease Vaccine Market Report 2026

Meningococcal Disease Vaccine Market Overview

• Meningococcal Disease Vaccine market size has reached to $2.59 billion in 2025 • Expected to grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Government Immunization Programs Fueling The Growth Of The Market Due To Increasing Access Awareness And Mandates • Market Trend: Advancements In Meningococcal Disease Vaccine Development And Serogroup Coverage Expansion • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Meningococcal Disease Vaccine Market?

The meningococcal disease vaccine refers to a vaccine that protects against meningococcal disease, a serious bacterial infection caused by the bacterium Neisseria meningitidis. This disease can lead to meningitis (inflammation of the membranes around the brain and spinal cord) and septicemia (blood poisoning), both of which can be life-threatening. The main types of meningococcal disease vaccines are conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines enhance immunity by linking bacterial sugars to proteins, offering effective protection against strains A, C, W, and Y, especially for adolescents and high-risk individuals. It is specifically available for various age groups, such as infants, children, adults, and older adults, for several indications, including preventive vaccination, post-exposure prophylaxis, travel-related vaccination, and outbreak response. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and is used by various end-users including hospitals, specialty clinics, home care, and others.

What Is The Meningococcal Disease Vaccine Market Growth Forecast?

The meningococcal disease vaccine market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising global travel and migration, increasing focus on preventive healthcare, expansion of vaccine coverage in emerging economies, growth in adolescent immunization initiatives, advancement in vaccine research and development. Major trends in the forecast period include rising adoption of conjugate and recombinant vaccines, expansion of routine immunization programs, increasing focus on adolescent and adult vaccination, growth in travel-related and outbreak-driven vaccination, higher emphasis on early preventive immunization.

What Is The Driver Of The Meningococcal Disease Vaccine Market?

The increasing government immunization programs are expected to propel the growth of the meningococcal disease vaccine market going forward. Government immunization programs are health initiatives that offer free or low-cost vaccines to safeguard communities against infectious diseases. Government immunization programs are growing due to a heightened emphasis on preventing infectious diseases and alleviating healthcare burdens through widespread vaccinations. Government immunization programs drive the growth of meningococcal vaccines by expanding access and increasing vaccination rates while raising awareness and reducing disease incidence. They also create demand by mandating vaccinations and promoting public health. For instance, in April 2024, according to the Pan American Health Organization (PAHO), a US-based specialized agency, the 22nd Vaccination Week in the Americas (VWA), with the theme Engage now to protect your future. GetVax was launched aiming to increase vaccination coverage, especially in underserved areas, by administering over 65 million doses. The initiative focused on combating misinformation and enhancing access to vaccines through community engagement and tailored campaigns. Therefore, the increasing government immunization programs driving the growth of the meningococcal disease vaccine industry.

Key Players In The Global Meningococcal Disease Vaccine Market

Major companies operating in the meningococcal disease vaccine market are Pfizer Inc, Merck & Co Inc, Sanofi SA, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Biovac Institute, Bio Manguinhos, Finlay Institute of Vaccines, Walvax Biotechnology Co Ltd, CSL Limited, China National Biotec Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Hangzhou Jinjiang Group Co Ltd, Shenzhen Kangtai Biological Products Co Ltd, Panacea Biotec, Biological E Limited, Instituto Butantan, Incepta Pharmaceuticals Ltd, Bio Med Pvt Ltd, Bharat Biotech International Ltd, Zhejiang Tianyuan Bio Pharmaceutical Co Ltd, Beijing Tiantan Biological Products Co Ltd.

Global Meningococcal Disease Vaccine Market Trends and Insights

Major companies operating in the meningococcal disease vaccine market are focused on developing advanced products, such as pentavalent meningococcal vaccines, to expand serogroup coverage, streamline immunization schedules, and improve disease prevention. A pentavalent meningococcal vaccine is an advanced immunization solution that targets five major serogroups of Neisseria meningitidis in a single dose, reducing the need for multiple separate vaccinations and improving compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical company, announced the Food and Drug Administration (FDA) approval for PENBRAYA, the first and only vaccine for the prevention of meningococcal disease in individuals aged 10 to 25 years. This innovative vaccine combines components from two existing meningococcal vaccines, Trumenba and Nimenrix, to protect against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis that cause the majority of invasive meningococcal disease (IMD) globally. PENBRAYA represents a significant advancement in meningococcal disease prevention, offering the broadest serogroup coverage of any meningococcal vaccine available in the U.S. and potentially simplifying the vaccination schedule by reducing the total number of doses required for full protection.

What Are Latest Mergers And Acquisitions In The Meningococcal Disease Vaccine Market?

In September 2023, Biovac, a South Africa-based biopharmaceutical company, partnered with EuBiologics Co. Ltd. to empower Africa through local vaccine innovation and self-reliance. The partnership aims to transfer technology and locally manufacture meningococcal meningitis pentavalent conjugate vaccine in Africa, addressing critical health needs in the meningitis belt and advancing the continent’s vaccine self-sufficiency. EuBiologics Co., Ltd. is a South Korea-based manufacturer of pentavalent meningococcal conjugate vaccine.

What Defines the Meningococcal Disease Vaccine Market?

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Meningococcal Disease Vaccine Market Report 2026?

The meningococcal disease vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal disease vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.